Back to top
more

West Pharmaceutical Services (WST)

(Delayed Data from NYSE)

$239.26 USD

239.26
644,194

0.00 (0.00%)

Updated Aug 1, 2025 03:59 PM ET

After-Market: $239.18 -0.08 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (46 out of 246)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Add DexCom (DXCM) to Your Portfolio

by Zacks Equity Research

DexCom (DXCM) raises its 2019 revenue and EPS guidance.

Zacks Equity Research

Here's Why You Should Hold on to Allscripts Stock for Now

by Zacks Equity Research

Allscripts (MDRX) is gaining steadily from strategic acquisitions and solid prospects in Sunrise EHR platform. However, integration risks remain a woe.

Zacks Equity Research

Here's Why You Should Bet on Integer Holdings Stock Now

by Zacks Equity Research

Integer Holdings (ITGR) continues to benefit from portfolio management, strong foothold in the broader MedTech space and rising Non-Medical sales.

Zacks Equity Research

LHC Group Expands Partnership With Tennessee-Based Medalogix

by Zacks Equity Research

Management at LHC Group (LHCG) expects to complete the expansion by the first quarter of 2020.

Zacks Equity Research

Here's Why You Should Invest in Cardinal Health Stock Now

by Zacks Equity Research

Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment.

Zacks Equity Research

NextGen Healthcare Boosts Patient Care With CHC Strategies

by Zacks Equity Research

NextGen Healthcare (NXGN) is likely to boost presence in health management with CHC Strategies delivering quality medical care through the company's Population Health platform.

Zacks Equity Research

LHC Group Set to Gain From Expansion of LifePoint Health JV

by Zacks Equity Research

LHC Group (LHCG) expects approximately $5.4 million in annualized revenues from this transaction.

Zacks Equity Research

Here's Why You Should Retain NextGen Healthcare for Now

by Zacks Equity Research

NextGen Healthcare (NXGN) is gaining traction from the U.S. RCM market and the growing EHR market. However, margin pressure remains a concern.

Zacks Equity Research

PDCO vs. WST: Which Stock Is the Better Value Option?

by Zacks Equity Research

PDCO vs. WST: Which Stock Is the Better Value Option?

Zacks Equity Research

Here's Why You Should Retain Wright Medical Stock For Now

by Zacks Equity Research

Wright Medical (WMGI) is gaining traction from strong international presence and robust product portfolio. However, adverse forex continues to raise concerns.

Zacks Equity Research

Here's Why You Should Hold on to Ecolab (ECL) Stock for Now

by Zacks Equity Research

Ecolab (ECL) slashes 2019 EPS view owing to foreign exchange headwinds.

Zacks Equity Research

Here's Why You Should Hold on to Cerner (CERN) Stock Now

by Zacks Equity Research

Cerner (CERN) is gaining traction from prudent strategic deals and big data based EHR system. However, weak margins remain a woe.

Zacks Equity Research

Here's Why You Should Retain Nevro (NVRO) Stock for Now

by Zacks Equity Research

Nevro (NVRO) is gaining traction from strengthening international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.

Zacks Equity Research

Here's Why You Should Hold On to HMS Holdings (HMSY) Stock

by Zacks Equity Research

HMS Holdings (HMSY) is gaining traction from growing PI and TPM analytical services. However, high debt continues to raise concerns.

Zacks Equity Research

XRAY or WST: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

XRAY vs. WST: Which Stock Is the Better Value Option?

Zacks Equity Research

West Pharmaceutical Services (WST) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

West Pharmaceutical (WST) delivered earnings and revenue surprises of 11.27% and 0.81%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate West Pharmaceutical Services (WST) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

West Pharmaceutical (WST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

ABC vs. WST: Which Stock Is the Better Value Option?

by Zacks Equity Research

ABC vs. WST: Which Stock Is the Better Value Option?

Zacks Equity Research

ABC vs. WST: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

ABC vs. WST: Which Stock Is the Better Value Option?

Zacks Equity Research

West Pharmaceutical (WST) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

West Pharmaceutical (WST) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

MCK vs. WST: Which Stock Is the Better Value Option?

by Zacks Equity Research

MCK vs. WST: Which Stock Is the Better Value Option?

Zacks Equity Research

Will West Pharmaceutical Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor West Pharmaceutical.

Zacks Equity Research

West Pharmaceutical (WST) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research

West Pharmaceutical (WST) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

West Pharmaceutical Services (WST) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

West Pharmaceutical (WST) delivered earnings and revenue surprises of 23.61% and 1.68%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Medical Products' Earnings Roster for Jul 25: SYK, BAX & More

by Urmimala Biswas

Encouraging growth in the emerging markets is likely to be a bonus for the medical products space this earnings season.